Effect of erythropoietin on urinary liver-type fatty-acid-binding protein in patients with chronic renal failure and anemia

American Journal of Nephrology

Volumn 26, Issue 3, 2006, Pages 276-280

  Nakamura, Tsukasa ^a   Sugaya, Takeshi ^b   Kawagoe, Yasuhiro ^a   Suzuki, Tsukasa ^a   Ueda, Yoshihiko ^c   Koide, Hikaru ^d  

^a Shinmatsudo Central General Hospital   (Japan)

^b RIKEN KOBE INSTITUTE   (Japan)

^c DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KOTO HOSPITAL   (Japan)

Author keywords

Anemia; Chronic renal failure; Erythropoietin; Liver type fatty acid binding protein

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID BINDING PROTEIN; FLUINDOSTATIN; HEMOGLOBIN; LIVER PROTEIN; PITAVASTATIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPOXIA; INTERVENTION STUDY; KIDNEY TUBULE; LIVER; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANEMIA; ERYTHROPOIETIN, RECOMBINANT; FATTY ACID-BINDING PROTEINS; FEMALE; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33746330409     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093934     Document Type: Article

References (21)

1. Eckardt KU: Pathophysiology of renal anemia. Clin Nephrol 2000;53(1 Suppl):S2-S8.
2. Grune T, Sommerburg O, Siems WG: Oxidative stress in anemia. Clin Nephrol 2000;53(1 Suppl):S18-S22.
3. Abdelrahman M, Sharples EJ, McDonald MC, Collin M, Patel NS, Yaqoob MM, Thiemermann C: Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 2004;22:63-69.
4. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, Yaqoob MM: Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004;15:2115-2124.
5. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW: Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 2004;19:348-355.
6. Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hikawa A, Hirano N, Goto A, Omata M: Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 2004;143:23-30.
7. Ishimitsu T, Ohta S, Saito M, Teranishi M, Inada H, Yoshii M, Minami J, Ono H, Hikawa A, Shibata N, Sugaya K, Kamijo A, Kimura K, Ohrui M, Matsuoka H: Urinary excretion of liver fatty acid-binding protein in health-check participants. Clin Exp Nephrol 2005;9:34-39.
8. Ayus JC, Go AS, Valderrabano F, Verde E, de Vinuesa SG, Achinger SG, Lorenzo V, Arieff AI, Luno J: Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dl. Kidney Int 2005;68:788-795.
9. Kamijo A, Sugaya T, Hikawa A, Okada M, Okuma F, Yamanouchi M, Honda A, Okabe M, Fujino T, Hirata Y, Omata M, Kaneko R, Fujii H, Fukamizu A, Kimura K: Urinary excretion of fatty acid binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004;165:1243-1255.
10. McClellan WM, Jurkovitz C, Abramson J: The epidemiology and control of anaemia among pre-ESRD patients with chronic kidney disease. Eur J Clin Invest 2005;35(Suppl 3):58-65.
11. Heyman SN, Rosenberger C, Rosen S: Erythropoietin: a potential remedy for renal tubular injury? Kidney Int 2004;65:737-738.
12. Teplan V, Schuck O, Knotek A, Hajny J, Horackova M, Kvapil M: Enhanced metabolic effect of erythropoietin and keto acids in CRF patients on low-protein diet: Czech multicenter study. Am J Kidney Dis 2003; 41(Suppl 1):S26-S30.
13. Lee SH, Li C, Lim SW, Ahn KO, Choi BS, Kim YS, Moon IS, Kim J, Bang BK, Yang CW: Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am J Nephrol 2005;25:64-76.
14. Rossert J, Fouqueray B, Boffa JJ: Anemia management and the delay of chronic renal failure progression. J Am Soc Nephrol 2003; 14(7 Suppl 2):S173-S177.
15. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC: Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004;66:753-760.
16. Matthys E, Patel Y, Kreisberg J, Stewart JH, Venkatachalam M: Lipid alterations induced by renal ischemia: pathogenic factor in membrane damage. Kidney Int 1984;26:153-161.
17. Kanauchi M, Nishioka H, Hashimoto T: Oxidative DNA damage and tubulointerstitial injury in diabetic nephropathy. Nephron 2002;91:327-329.
18. Stoll LL, McCormick ML, Denning GM, Weintraub NL: Antioxidant effects of statins. Drugs Today (Barc) 2004;40:975-990.
19. Manotham K, Tanaka T, Matsumoto M, Ohse T, Miyata T, Inagi R, Kurokawa K, Fujita T, Nangaku M: Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol 2004;15:1277-1288.
20. Fliser D, Wagner KK, Loos A, Tsikas D, Haller H: Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005;16:1135-1140.
21. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Omata M, Kimura K: Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem 2006;284:175-182.